Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) is anticipated to release its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.75) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kyverna Therapeutics Stock Performance

Kyverna Therapeutics stock traded up $0.12 during midday trading on Tuesday, hitting $9.12. The stock had a trading volume of 357,783 shares, compared to its average volume of 867,113. The firm’s fifty day moving average is $8.73 and its two-hundred day moving average is $8.21. The company has a market capitalization of $552.03 million, a PE ratio of -2.50 and a beta of 2.05. Kyverna Therapeutics has a 52-week low of $1.92 and a 52-week high of $13.67. The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.11.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Kyverna Therapeutics in a report on Thursday, April 23rd. Wall Street Zen lowered Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.67.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio purchased a new stake in Kyverna Therapeutics during the 3rd quarter valued at approximately $28,000. Federated Hermes Inc. grew its position in shares of Kyverna Therapeutics by 36.6% during the fourth quarter. Federated Hermes Inc. now owns 20,705 shares of the company’s stock valued at $195,000 after purchasing an additional 5,547 shares in the last quarter. Rhumbline Advisers grew its position in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares in the last quarter. Bank of America Corp DE grew its position in shares of Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after purchasing an additional 6,400 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Kyverna Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock valued at $7,936,000 after purchasing an additional 9,858 shares in the last quarter. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.